Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GKT137831 in Idiopathic Pulmonary Fibrosis
NCT03865927Phase 2Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Sep 2020
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing GKT137831 with Placebo (2 arms). Primary endpoint: Surrogate Biomarker of Oxidative Stress by Mass Spectroscopy at 24 weeks. Started Sep 2020; status: completed.
02
Drugs
setanaxib
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT03865927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03865927.